Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Sell
RSI(14)
37.892
Neutral
STOCH(KDJ)(9,3,3)
28.770
Neutral
ATR(14)
0.043
Low Volatility
CCI(14)
-33.154
Neutral
Williams %R
70.224
Sell
TRIX(12,20)
-0.808
Sell
StochRSI(14)
100.000
Buy
Xtant Medical Holdings Inc
XTNT0.591USD
+0.021+3.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
82.78MMarket Cap
45.70P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Xtant Medical Holdings Inc
Currency: USD Updated: 2026-02-06Key Insights
Xtant Medical Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 1.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xtant Medical Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Xtant Medical Holdings Inc Highlights
StrengthsRisks
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 102.29% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 117.27M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 45.70, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 713.91K shares of this stock.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
1.500
Target Price
+163.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Xtant Medical Holdings Inc is 8.00, ranking 64 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 33.26M, representing a year-over-year increase of 19.04%, while its net profit experienced a year-over-year increase of 126.04%.
Score
Financials
7.08
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.94
Operational Efficiency
8.75
Growth Potential
7.08
Shareholder Returns
7.15
Xtant Medical Holdings Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Xtant Medical Holdings Inc is 8.36, ranking 27 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 45.70, which is 405.62% below the recent high of 231.05 and 345.81% above the recent low of -112.32.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 39/205
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Xtant Medical Holdings Inc is 9.00, ranking 6 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 1.50, with a high of 1.50 and a low of 1.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
1.500
Target Price
+163.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
114
Total
6
Median
9
Average
Company name
Ratings
Analysts
Xtant Medical Holdings Inc
XTNT
2
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Medtronic PLC
MDT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Xtant Medical Holdings Inc is 6.76, ranking 87 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.70 and the support level at 0.51, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.590
Buy
MA10
0.602
Sell
MA20
0.633
Sell
MA50
0.679
Sell
MA100
0.699
Sell
MA200
0.659
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Xtant Medical Holdings Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 114.61%, representing a quarter-over-quarter increase of 100.58%. The largest institutional shareholder is The Vanguard, holding a total of 2.27M shares, representing 1.62% of shares outstanding, with 0.27% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Nantahala Capital Management, LLC
Lytton (Laurence W)
Vizirgianakis (Stavros G)
AWM Investment Company, Inc.
Browne (Sean E.)
Beeson (Jonn R.)
Bakewell (John K)
Neils (Scott C)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Xtant Medical Holdings Inc is 2.44, ranking 158 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is -0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-0.30
VaR
+6.75%
240-Day Maximum Drawdown
+38.04%
240-Day Volatility
+112.78%
Return
Best Daily Return
60 days
+14.90%
120 days
+14.90%
5 years
+23.68%
Worst Daily Return
60 days
-8.57%
120 days
-8.57%
5 years
-25.54%
Sharpe Ratio
60 days
-1.39
120 days
-0.04
5 years
+0.03
Risk Assessment
Maximum Drawdown
240 days
+38.04%
3 years
+74.78%
5 years
+82.47%
Return-to-Drawdown Ratio
240 days
+0.11
3 years
-0.06
5 years
-0.17
Skewness
240 days
+0.57
3 years
+0.38
5 years
+0.34
Volatility
Realised Volatility
240 days
+112.78%
5 years
+103.51%
Standardised True Range
240 days
+9.19%
5 years
+11.02%
Downside Risk-Adjusted Return
120 days
-7.03%
240 days
-7.03%
Maximum Daily Upside Volatility
60 days
+61.75%
Maximum Daily Downside Volatility
60 days
+46.30%
Liquidity
Average Turnover Rate
60 days
+0.05%
120 days
+0.08%
5 years
--
Turnover Deviation
20 days
-34.30%
60 days
-34.91%
120 days
+5.01%
Peer Comparison
Healthcare Equipment & Supplies
Xtant Medical Holdings Inc
XTNT
7.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
ALGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
